Parabilis Medicines, Inc. (PBLS)
30.37
+1.84
(+6.45%)
USD |
NASDAQ |
Nov 09, 16:00
29.77
-0.60
(-1.98%)
After-Hours: 20:00
Parabilis Medicines Net Income (Quarterly) : -52.46M for June 30, 2026
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -52.46M |
| March 31, 2026 | -45.32M |
| Date | Value |
|---|---|
| June 30, 2025 | -34.81M |
| March 31, 2025 | -38.33M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| Arrowhead Pharmaceuticals, Inc. | -178.92M |
| Oncolytics Biotech, Inc. | -9.442M |
| Sangamo Therapeutics, Inc. | -31.00M |
| Sarepta Therapeutics, Inc. | -28.46M |
| Anixa Biosciences, Inc. | -2.625M |
Net Income (Quarterly) Related Metrics
| Revenue (Quarterly) | 0.148M |
| Total Expenses (Quarterly) | 52.61M |
| EPS Diluted (Quarterly) | -0.5421 |
| Enterprise Value | 2.678B |
| Gross Profit Margin (Quarterly) | -300.7% |
| Profit Margin (Quarterly) | -35.45K% |
| Earnings Yield | -6.30% |
| Normalized Earnings Yield | -6.197 |